- Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression
Watch NRX Pharmaceuticals' latest callNRX Pharmaceuticals (NASDAQ:NRXP) Q2 2026 Earnings Call · Replay · Aug 17Read the transcript of NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2026 Earnings CallNRX Pharmaceuticals, Inc. on 6ix
Story so far
- NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
- NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
- NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
Earlier from NRX Pharmaceuticals
- NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support
- NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
- NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
- NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
- NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Later from NRX Pharmaceuticals
- NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain
- NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference
- NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
- NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression
- NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
Follow NRX Pharmaceuticals into a list and get an email when it puts out news.
Follow NRX Pharmaceuticals